ADC Pipeline Focus Will Advance Preclinical Drug Development

Key Takeaways

• Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential.
  
• Workforce reduction and externalization aim to improve margins and extend the cash runway, while partnerships and out-licensing bolster financial flexibility.
  
• Sutro Biopharma faces challenges in managing R&D expenses, operational inefficiencies, and strategic risks, impacting earnings and revenue with reliance on partnerships adding uncertainties.

Catalysts

Operates as a oncology company.

• Sutro's strategic restructuring and focus on prioritizing three wholly-owned preclinical programs in its ADC pipeline, with plans to submit three INDs starting in 2025, is expected to drive future revenue growth by accelerating the development of potentially best-in-class drugs.
  
• The reduction in workforce by nearly 50% and externalization of manufacturing capabilities are anticipated to improve net margins by decreasing operational costs, thus extending the company's cash runway into at least Q4 of 2026.
  
• The company's proprietary ADC design platform enables precise drug development that can target harder-to-treat cancers, poised to enhance revenue and earnings as these new treatments potentially capture significant market share.
  
• Continued exploration of global out-licensing opportunities for luvelta could provide nondilutive capital and partnership-driven revenues, bolstering financial flexibility and reducing the reliance on company-led investments.
  
• Established partnerships with world-class partners like Astellas and Ipsen highlight Sutro's potential to secure additional collaborations and partnerships, offering potential revenue streams from milestones and licensing agreements, positively impacting overall earnings.

Sutro Biopharma Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Sutro Biopharma's revenue will decrease by 37.3% annually over the next 3 years.
• Analysts are not forecasting that Sutro Biopharma will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Sutro Biopharma's profit margin will increase from -186.5% to the average US Biotechs industry of 12.8% in 3 years.
• If Sutro Biopharma's profit margin were to converge on the industry average, you could expect earnings to reach $3.2 million (and earnings per share of $0.16) by about April 2029, up from -$191.1 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 248.7x on those 2029 earnings, up from -2.9x today. This future PE is greater than the current PE for the US Biotechs industry at 17.8x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.18%, as per the Simply Wall St company report.

Risks

• The decision to deprioritize the development of luvelta due to a lack of sufficient capital to bring it to market indicates challenges in managing R&D expenses, which could impact overall earnings.
  
• The 50% workforce reduction and externalization of cell-free manufacturing capabilities highlight potential operational inefficiencies, which may affect profit margins.
  
• The strategic pivot to focus on early-stage ADC programs involves inherent risks, including drug development uncertainties and lengthy timeframes before potential revenue generation, impacting revenue projections.
  
• Relatively high current expenditures in comparison with expected cost savings suggest potential difficulties in achieving the anticipated decline in cash burn and improving net margins in the short term.
  
• Dependency on finding partners for programs like luvelta introduces market uncertainties and could lead to delays or unfavorable terms in collaboration deals, affecting revenue streams and profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $32.11 for Sutro Biopharma based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $55.0, and the most bearish reporting a price target of just $9.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $25.2 million, earnings will come to $3.2 million, and it would be trading on a PE ratio of 248.7x, assuming you use a discount rate of 7.2%.
• Given the current share price of $33.33, the analyst price target of $32.11 is 3.8% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.